Joanne M. Langley

6299 South Street
Halifax, NS, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 198 publications

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.

Journal: medRxiv : the preprint server for health sciences

Published: June 29, 2026

Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.

Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.

Journal: Human vaccines & immunotherapeutics

Published: June 10, 2026

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV

Published: February 25, 2026

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study.

Journal: Human vaccines & immunotherapeutics

Published: February 17, 2026

Changes in hospital admissions associated with pediatric respiratory syncytial virus after the COVID-19 pandemic in Canada: an active surveillance study.

Changes in hospital admissions associated with pediatric respiratory syncytial virus after the COVID-19 pandemic in Canada: an active surveillance study.

Journal: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Published: February 02, 2026

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada.

Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada.

Journal: Human vaccines & immunotherapeutics

Published: January 13, 2026

Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants: A Meta-Analysis.

Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants: A Meta-Analysis.

Journal: JAMA pediatrics

Published: December 22, 2025

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

Journal: Vaccine

Published: November 18, 2025

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Journal: Vaccine

Published: August 25, 2025

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Journal: Vaccine

Published: July 30, 2025

Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.

Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.

Journal: Vaccines

Published: July 15, 2025

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Journal: Nature immunology

Published: July 14, 2025

Showing 1-12 of 198

Last Updated: 09/26/2026